Key result
Dual muscle-liver rAAV transduction imposes transgene-specific immune tolerance, eliminating CD8+ T cell responses and enabling long-term muscle transgene engraftment despite preexisting immunity.
Why the study?
Immune responses to therapeutic transgenes from B cells and cytotoxic T cells recruited upon gene transfer are a hurdle to treating monogenic muscle disorders.
Dual muscle-liver transduction can overcome preexisting immunity to allow successful muscle transgene engraftment by inducing T cell exhaustion and tolerance.
May enable muscle gene therapy despite preexisting immunity in models; leaves open translation to human trials.
Immune responses to therapeutic transgenes are a potential hurdle to treat monogenic muscle disorders. These responses result from the neutralizing activity of transgene-specific B cells and cytotoxic T cells recruited upon gene transfer. We explored here how dual muscle-liver expression of a foreign transgene allows muscle transgene engraftment after adenoassociated viral vector delivery. We found in particular that induction of transgene-specific tolerance is imposed by concurrent muscle and liver targeting, resulting in the absence of CD8+ T cell responses to the transgene. This tolerance can be temporally decoupled, because transgene engraftment can be achieved in muscle weeks after liver transduction. Importantly, transgene-specific CD8+ T cell tolerance can be established despite preexisting immunity to the transgene. Whenever preexisting, transgene-specific CD4+ and CD8+ memory T cell responses are present, dual muscle-liver transduction turns polyclonal, transgene-specific CD8+ T cells into typically exhausted T cells with high programmed cell death 1 (PD-1) expression and lack of IFN-γ production. Our results demonstrate that successful transduction of muscle tissue can be achieved through liver-mediated control of humoral and cytotoxic T cell responses, even in the presence of preexisting immunity to the muscle-associated transgene.
No takes yet. Share an insight, caveat, or question.
Bartolo et al. (2019) studied Immune response to rAAV gene transfer. Dual muscle-liver rAAV transduction vs. rAAV1 i.m. alone was evaluated on Frequency of OVA-specific CD8+ T cells and OVA mRNA expression in muscle. Dual muscle-liver rAAV transduction imposes transgene-specific immune tolerance, eliminating CD8+ T cell responses and enabling long-term muscle transgene engraftment despite preexisting immunity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: